A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer-Reference-Cited by-同舟云学术

A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer

Published:2013-12 Issue:6 Volume:22 Page:1171-1177
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Tryfonidis K.,Boukovinas I.,Xenidis N.,Christophyllakis C.,Papakotoulas P.,Politaki E.,Malamos N.,Polyzos A.,Kakolyris S.,Georgoulias V.,Mavroudis D.

Funder

Cretan Association for Biomedical Research (CABR

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference38 articles.

1. Chemotherapy for metastatic breast cancer;Mayer;Hematol Oncol Clin North Am,2007

2. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer;Miller;J Clin Oncol,2005

3. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer;Mavroudis;Ann Oncol,2009

4. NCCN clinical practice guidelines, invasive breast cancer;Carlson;J Natl Compr Cancer Netw,2007

5. Single agent versus combination chemotherapy for metastatic breast cancer;Carrick;Cochrane Database Syst Rev,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized Phase III Trial Comparing Epirubicin/ Doxorubicin Plus Docetaxel and Epirubicin/ Doxorubicin Plus Paclitaxel as First Line Treatment in Women with Advanced Breast Cancer;Journal for Research in Applied Sciences and Biotechnology;2023-06-12

2. Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis;Diagnostics;2022-11-25

3. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises;JNCI: Journal of the National Cancer Institute;2019-10-25

4. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer ( CBCRT 01);International Journal of Cancer;2017-12-23

5. Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis;Scientific Reports;2017-03-24